Press Release: Oak enters battle against malaria

Fresh from PR Log: Oxnard, CA – Oxnard-based pharmaceutical start-up Oak Therapeutics successfully concluded the pre-clinical phase of its anti-malarial medication Artelutrine™. Artelutrine™ is a reformulation of a highly effective, WHO-recommended combination therapy of the active ingredients Artemether and Lumefantrine using Oak Therapeutics novel delivery system, oral dissolvable strips (ODS).